Clinical Trials Logo
  1. Home
  2. Pancreas Adenocarcinoma
  3. NCT04821219

Personalized Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids

Pancreas Adenocarcinoma Clinical Trial

Official title:
Establishing a Platform for Personalized Approach to the Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids

Clinical Trial Summary

This study is designed to prospectively investigate the feasibility of establishing patient-derived tumoroids (PDT) as a platform for a personalized approach for response prediction and guide optimal neoadjuvant and/or adjuvant approach. PDT will be investigated to determine drug sensitivity, predict the response to chemotherapy agents and radiation therapy, and validate this response in treated patients, and to establish the feasibility of PDT as a platform for a personalized approach to guide multimodality treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04821219
Study type Interventional
Source Mayo Clinic
Contact
Status Withdrawn
Phase N/A
Start date January 1, 2022
Completion date December 31, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06065891 - Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT01774162 - EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration N/A
Recruiting NCT04164602 - The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
Recruiting NCT05325281 - CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma Phase 1
Completed NCT05161013 - A Proof-of-Concept Study Evaluating LINFU™ N/A
Recruiting NCT05470920 - Genetic Testing Decision Aid N/A
Recruiting NCT04099134 - PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma
Completed NCT05518071 - FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1 Phase 2
Withdrawn NCT04045730 - The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma. Phase 2
Recruiting NCT06160596 - Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
Recruiting NCT04636788 - Circulating Extracellular Exosomal Small RNA as Potential Biomarker for Human Pancreatic Cancer N/A
Recruiting NCT04435067 - Evaluation of Clinical, Radiomics and Molecular Features of Lung Metastasis in PDAC Patients (LUMACA Trial)
Recruiting NCT04571294 - Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy N/A
Recruiting NCT06451497 - Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT03472716 - The βIG-H3 Protein: a New Marker in PANCreatic Adenocarcinoma (BIGHPANC)
Completed NCT03532347 - Endoscopic Ultrasound Guided Tissue Sampling (The SharkBITE Study) N/A
Withdrawn NCT06090318 - Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss Phase 1/Phase 2
Not yet recruiting NCT06381882 - The Role of the Human Microbiome in Patients After Pancreatic Resection.
Recruiting NCT03544255 - Drug Screening of Pancreatic Cancer Organoids Developed From EUS-FNA Guided Biopsy Tissues